公开(公告)号：EP1051625A1

公开(公告)日：2000-11-15

申请号：EP99903415.0

申请日：1999-01-27

申请人： Du Pont Pharmaceuticals Company

发明人： SEIFFERT, Dietmar, A. ,  BILLHEIMER, Jeffrey, T. ,  BRETH, Leah, A. ,  BURN, Timothy, C. ,  DICKER, Ira, B. ,  GEORGE, Henry, J. ,  HOLLIS, Jeannine, M. ,  HOLLIS, Gregory, F. ,  KOCHIE, Jennifer, E. ,  O'NEIL, Karyn, T.

IPC分类号： G01N33/68 ,  G01N33/566 ,  C07K16/18 ,  C12N5/18 ,  C12N15/13

CPC分类号： G01N33/6893 ,  C07K14/70557 ,  C07K16/2848 ,  G01N33/566 ,  G01N33/68 ,  G01N2333/70546 ,  G01N2500/00 ,  Y10S435/968 ,  Y10S436/811

摘要： This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABs) that bind to integrins in the presence of an integrin agonist and/or antagonist, and to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays and to procedures for treating blood samples, which dissociate antibodies to GPIIb/IIIa from the platelet surface, thereby increasing the recovery from the platelet supernatant. This invention also relates to the use of different GPIIb/IIIa preparations to identify patients at risk for early-onset thrombocytopenia upon treatment with GPIIb/IIIa antagonist/agonists, thereby increasing the specificity of antibody detection.